About BridGene Biosciences
BridGene Biosciences is a Healthcare company based in Sunnyvale (United States) founded in 2018 by Irene Yuan and Ping Cao. Developer of small-molecule drugs for the treatment of cancer. BridGene Biosciences has raised $78.5 million across 5 funding rounds from investors including HHS, Lapam Capital and D Yee Capital. The company has 25 employees. Its chief executive, as recorded, is Ping Cao. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Diversified. Its competitors include BridgeBio, Spark Therapeutics and Alnylam; 3 of its 3 listed competitors have raised funding.
Company details
BridGene Biosciences was founded in 2018 in Sunnyvale, United States, as a biotechnology firm focused on oncology therapeutics. Small-molecule drugs targeting cancer are developed through the proprietary Chemoproteomics platform, IMTAC. This technology is employed to screen compounds against the full proteome in live cells, facilitating identification of candidates for difficult-to-drug targets implicated in disease progression. Operations center on advancing these discoveries toward clinical applications.
- Headquarters Sunnyvale, United States
- Employees 25
- Founders Irene Yuan, Ping Cao
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website bridgenebio.com
- Social LinkedIn X
- Total Equity Funding$78.5M (USD)
in 5 rounds
- Latest Funding Round$28M (USD), Series B
Oct 2025
- InvestorsHHS
& 8 more
- Employee Count25
Funding Insights of BridGene Biosciences
BridGene Biosciences has successfully raised a total of $78.5M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $28 million completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $78.5M
- Total Rounds 5
- Last Round Series B — $28M
- First Round $223,000
(Sep 2018)
- Investors Count 9
All 5 funding rounds of BridGene Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2025 | $28M | Series B | – | Bayland Capital | |
| Jul 2022 | $38.5M | Series B | – | Lapam Capital, Deyi Capital | – |
| May 2021 | $12M | Series A | – | Kaitai Capital Management | – |
| Sep 2020 | $298,928 | Grant | – | – | |
| Sep 2018 | $223,000 | Grant | – | – |
9 investors in total: 9 institutional.
Investors in BridGene Biosciences
BridGene Biosciences has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, Lapam Capital and D Yee Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| lapamcapital.com | ||||
Venture capital services are offered to support entrepreneurial growth. | dyeecapital.com | Xiamen, China | ||
| junsoncapital.com | ||||
Kaitai Capital is engaged in innovation investment management services. | kaitaicapital.com | Hangzhou, China | ||
Seed and early stage tech and life sciences focused VC firm investing in companies in China | grainsvalley.com | Beijing, China | ||
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Delivers comprehensive financial services solutions. | 1995 | gtjai.com | Hong Kong, China | |
| proximaventures.com |
Investor details for BridGene Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of BridGene Biosciences
2 people are tracked at BridGene Biosciences (2 in leadership); the tracked headcount is 25.
| Name | Role | Group |
|---|---|---|
Irene Yuan | Co-Founder & Executive Vice President | Leadership |
Ping Cao | Co-Founder & CEO | Leadership |
Complete people profiles for BridGene Biosciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of BridGene Biosciences
3 dated milestones of BridGene Biosciences across 7 years, from founding to its latest funding, stage changes and deals.
- Founded BridGene Biosciences is founded.
- Funding First funding round of $223K.
- Funding Latest funding round, Series B, of $28.0M.
Competitors of BridGene Biosciences
BridGene Biosciences has 3 listed competitors in our database, 3 of them funded. They include BridgeBio, Spark Therapeutics and Alnylam.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. |
Detailed competitors of BridGene Biosciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as BridGene Biosciences (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Bridgene Biosciences
Complete news archive for BridGene Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BridGene Biosciences
BridGene Biosciences was founded in 2018.
BridGene Biosciences is headquartered in Sunnyvale, United States. It is registered at Sunnyvale, California, United States.
Ping Cao is the CEO of BridGene Biosciences, as recorded in our data. They have also founded this company.
BridGene Biosciences is a funded company, having raised a total of $78.5M across 5 funding rounds to date. The company's 1st funding round was a Grant of $223K, raised on Sep 2018.
BridGene Biosciences has 25 employees.
BridGene Biosciences was founded in 2018 in Sunnyvale, United States, as a biotechnology firm focused on oncology therapeutics. Small-molecule drugs targeting cancer are developed through the proprietary Chemoproteomics platform, IMTAC. This technology is employed to screen compounds against the full proteome in live cells, facilitating identification of candidates for difficult-to-drug targets implicated in disease progression. Operations center on advancing these discoveries toward clinical applications.
BridGene Biosciences's top competitors include Spark Therapeutics, BridgeBio and Alnylam.
BridGene Biosciences has 9 investors. Key investors include HHS, Lapam Capital, D Yee Capital, Junson Capital, and Kaitai Capital.